Zymeworks Inc. (NASDAQ:ZYME) Receives $35.70 Consensus PT from Brokerages

Zymeworks Inc. (NASDAQ:ZYME) has been given a consensus rating of “Moderate Buy” by the fourteen research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, ten have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $37.10.

ZYME has been the subject of several research reports. Wells Fargo & Company upgraded shares of Zymeworks from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $25.00 to $33.00 in a report on Friday, December 12th. Stifel Nicolaus increased their target price on shares of Zymeworks from $40.00 to $47.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. B. Riley Financial reissued a “buy” rating and set a $40.00 target price (up from $30.00) on shares of Zymeworks in a research note on Friday, November 21st. HC Wainwright boosted their price target on shares of Zymeworks from $32.00 to $46.00 and gave the company a “buy” rating in a report on Friday. Finally, Leerink Partners increased their price objective on Zymeworks from $52.00 to $58.00 and gave the stock an “outperform” rating in a report on Tuesday, March 3rd.

Zymeworks Price Performance

ZYME stock opened at $24.08 on Wednesday. The firm has a market capitalization of $1.78 billion, a P/E ratio of -22.30 and a beta of 1.23. Zymeworks has a 52-week low of $9.03 and a 52-week high of $28.49. The company’s 50 day simple moving average is $23.72 and its 200-day simple moving average is $21.17.

Zymeworks (NASDAQ:ZYME) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.20). The firm had revenue of $2.52 million for the quarter, compared to analysts’ expectations of $21.78 million. Zymeworks had a negative return on equity of 26.00% and a negative net margin of 76.56%.The company’s revenue for the quarter was down 91.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.31) earnings per share.

Zymeworks News Summary

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: HC Wainwright raised its price target to $46 and reiterated a Buy rating — the new target implies substantial upside from current levels. Benzinga
• Positive Sentiment: Stifel Nicolaus boosted its price target to $47, another significant upward revision that supports a bullish view on ZYME’s longer‑term recovery. Stifel Target
• Positive Sentiment: Leerink Partners published a bullish forecast for Zymeworks, contributing to the cluster of upgrades and positive analyst sentiment this week. Leerink Report
• Neutral Sentiment: Lifesci Capital updated its FY-2026 and quarterly EPS forecasts with mixed changes: it materially improved the FY-2026 loss estimate (from -$1.40 to -$0.68) and sharply raised Q2/Q3 outlooks, but it lowered the Q1 estimate — a mixed signal that improves multi‑quarter visibility while acknowledging near‑term pressure. Lifesci Estimates
• Negative Sentiment: Recent quarterly results (reported March 2) showed a meaningful EPS miss and a ~92% YoY revenue decline, leaving Zymeworks unprofitable with negative margins — fundamentals that likely temper enthusiasm and explain part of the intraday weakness despite upgrades. Earnings Detail

Insider Transactions at Zymeworks

In related news, insider Paul Andrew Moore sold 9,560 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $22.67, for a total value of $216,725.20. Following the completion of the sale, the insider owned 48,497 shares of the company’s stock, valued at approximately $1,099,426.99. The trade was a 16.47% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Kenneth Galbraith sold 30,424 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $22.67, for a total transaction of $689,712.08. Following the completion of the sale, the chief executive officer directly owned 226,842 shares of the company’s stock, valued at $5,142,508.14. This represents a 11.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 187,933 shares of company stock valued at $4,673,716 in the last quarter. Corporate insiders own 33.51% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ZYME. AQR Capital Management LLC grew its position in shares of Zymeworks by 86.0% in the first quarter. AQR Capital Management LLC now owns 48,485 shares of the company’s stock valued at $577,000 after purchasing an additional 22,411 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Zymeworks by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 32,385 shares of the company’s stock valued at $386,000 after purchasing an additional 1,427 shares during the period. Jane Street Group LLC raised its stake in shares of Zymeworks by 487.0% in the 1st quarter. Jane Street Group LLC now owns 135,763 shares of the company’s stock valued at $1,617,000 after buying an additional 112,636 shares in the last quarter. Bank of Montreal Can lifted its stake in Zymeworks by 6.7% during the second quarter. Bank of Montreal Can now owns 27,642 shares of the company’s stock worth $347,000 after purchasing an additional 1,730 shares during the period. Finally, Campbell & CO Investment Adviser LLC bought a new position in shares of Zymeworks during the 2nd quarter worth approximately $188,000. 92.89% of the stock is currently owned by institutional investors and hedge funds.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.